EDERRA Signs Letter of Intent with Dr. Anand Swaroop of Cepham for Strategic Production Partnership to Build the Infrastructure Behind the Next Genera
Partnership is designed to pair EDERRA’s farm-to-body functional nutrition thesis with Cepham’s evidence-based manufacturing capabilities and supply-chain rigor.
OCEANSIDE, Calif. and SOMERSET, N.J -- March 30, 2026 — EDERRA today announced it has entered into a Letter of Intent (LOI), dated March 26, 2026, with Cepham for a strategic manufacturing and production partnership designed to support EDERRA’s functional superfood product line, including its flagship formula, EMPWR+.
Under the LOI, the parties intend to negotiate definitive agreements under which Cepham would provide production and operational support to help EDERRA scale manufacturing in phases, strengthen sourcing and packaging execution, and accelerate product innovation.
The partnership represents a key milestone in EDERRA’s evolution from an emerging brand to a scalable wellness platform as demand grows for EMPWR+, its functional greens formula designed to support cellular detox and defense, gut health, cognitive performance, and longevity.
Rather than building manufacturing infrastructure internally, EDERRA is pursuing an asset-light scaling strategy by partnering with established science and manufacturing operators, a model increasingly adopted by next-generation wellness companies seeking to scale efficiently while maintaining integrity.
EDERRA’s brand is built around a farm-to-body philosophy that connects consumers more directly to ingredient sourcing and transparency. Cepham brings decades of experience in nutraceutical ingredient development, manufacturing quality systems, and global supply chain management.
“Investors today are funding execution engines, not just products,” said Vladi Delsoglio, Founder and CEO of EDERRA. “This LOI represents an important step toward building a scalable operational foundation that matches our farm-to-body promise. By aligning with Cepham’s science-first and operations-driven approach, we aim to de-risk supply, accelerate disciplined production expansion, and deploy capital more efficiently while focusing on demand generation and distribution.”
“EDERRA is building a brand that treats sourcing and transparency as a core product feature,” said Dr. Anand Swaroop, President of Cepham. “That philosophy aligns closely with our commitment to safety, science, and sustainability. We are excited to explore a partnership designed to help EDERRA scale while preserving the integrity, traceability, and quality expectations that modern consumers and sophisticated investors expect from next-generation wellness companies.”
The agreement also reflects growing investor interest in the longevity economy, functional nutrition, and preventive health sectors expected to experience sustained growth as healthcare continues to shift toward prevention and performance optimization.
As functional nutrition increasingly blurs the lines between supplements, food, and performance health, companies capable of combining brand development, scientific credibility, and operational scale may define the next decade of the category.
“This is about building a company designed to last decades, not just ride a trend,” Delsoglio added. “Execution ultimately separates brands that get attention from brands that build categories.”
About EDERRA
EDERRA is a California-based functional wellness company developing superfood formulations focused on longevity, cognitive performance, gut health, and daily wellness optimization. Its flagship product, EMPWR+, reflects the company’s farm-to-body philosophy, emphasizing ingredient transparency, sourcing integrity, and measurable functional benefits designed for modern wellness routines.
For more information, visit:
www.ederralyfe.com
About Cepham
Cepham is a U.S. nutraceutical company specializing in the development and manufacturing of evidence-based ingredients and delivery systems for the natural health industry. The company’s capabilities span ingredient research and development, manufacturing, and global supply chain operations.
For more information, visit:
www.cepham.com
Forward-Looking Statements
This press release contains forward-looking statements, including statements regarding expectations, intentions, and anticipated benefits related to the Letter of Intent and any potential definitive agreements. These statements involve risks and uncertainties, and actual results may differ materially from those expressed or implied. EDERRA undertakes no obligation to update forward-looking statements except as required by law.
###
Contact Information:
Vladi Delsoglio
+ (213) 952-7661
vladi@ederralyfe.com
https://www.facebook.com/profile.php?id=61559780021070
https://www.instagram.com/tryederra/
Sponsor Message
For millions of Americans, Canadian pharmacies provide an affordable solution for essential prescriptions such as Lipitor and Crestor to manage cholesterol, or Nexium for GERD and acid reflux. Patients managing chronic conditions often rely on insulin options like Humalog and Lantus for diabetes or Advair Diskus and Ventolin inhalers for asthma and COPD. Essential medications like Zoloft, Prozac, and Abilify support mental health by addressing conditions such as depression, anxiety, and bipolar disorder, while blood thinners like Eliquis, Plavix, and Xarelto help reduce the risk of stroke. Popular treatments for pain and inflammation, such as Celebrex, and thyroid replacement therapy like Synthroid, are also frequently ordered. Additionally, drugs such as Viagra and Cialis are effective for erectile dysfunction, and treatments like Januvia are used for controlling Type 2 diabetes. Excessive sleepiness and narcolepsy symptoms are managed effectively with wakefulness aids like Provigil and Nuvigil. Affordable options like Cymbalta for nerve pain and Aricept for Alzheimer's are made available to American patients through Canadian pharmacies.
